BeiGene | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

⟵ Back to Search Results

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Beigene Study ID

BGB-A317-Sitravatinib-203

ClinicalTrials.gov ID

NCT05461794

China Drug Trials ID

CTR20222088

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents